重组人白细胞介素-11治疗成人慢性难治性特发性血小板减少性紫癜临床观察

Clinical study of recombinant human interleukin-11 in treating chronic refractory idiopathic thrombocytopenic purpura

目的探讨重组人白细胞介素-11(rhIL-11)治疗成人慢性难治性特发性血小板减少性紫癜(ITP)的疗效和不良反应。方法24例成人慢性难治性ITP患者皮下注射rhIL-11,25μg/(kg·d),疗程14d,动态观察血常规,定期复查尿常规,大便常规,肝肾功能,心电图及凝血功能等。结果用药前血小板平均值为(21.0±16.8)×109/L,用药后最高值平均为(115.2±62.8)×109/L,两者比较差异有非常显著性(P≤0.01),综合评价疗效显效54.2%,总有效率100%,4例患者出现轻微不良反应,均在治疗过程中或停药后消失。结论rhIL-11治疗成人慢性难治性ITP具有良好的疗效,且不良反应轻微。

[Objective] To explore the efficacy and toxicity of recombinant human interleukin-11 in treating chronic refractory idiopathic thrombocytopenic purpura.[Method] 24 patients with chronic refractory idiopathic thrombocytopenic purpura were administered with 25 μg/(kg.d)rhIL-11 subcutaneously once daily for 14 days,Blood routine,urine routine,stool routine,the function of liver and kindney,electrocardiograph and coagulation function were monitored.[Result] The peak platelet count after treatment(115.2±62.8)×109/L was significantly greater than the mean platelet count before treatment [(21.0±16.8)×109/L,P ≤0.01].The evaluation of synthetic efficacy showed 52.4% of the apparent efficiency rate and 100% of the total efficiency rate.Few side effects occurred in four patients and they disappeared in the treating process or after withdrawal of rhIL-11.[Conclusion] rhIL-11 had satisfactory efficacy in the treatment of chronic refractory idiopathic thrombocytopenic purpura with few side effects.